Hostname: page-component-7479d7b7d-fwgfc Total loading time: 0 Render date: 2024-07-11T04:25:44.787Z Has data issue: false hasContentIssue false
  • English
  • Français

Treatment of Postanoxic Intention Myoclonus with Valproic Acid

Published online by Cambridge University Press:  18 September 2015

J. Bruni ,
L.J. Willmore  and
B.J. Wilder
J. Bruni
Affiliation:
Neurology Service, Veterans Administration Hospital and Department of Neurology, University of Florida College of Medicine, Gainesville, Florida
L.J. Willmore*
Affiliation:
Neurology Service, Veterans Administration Hospital and Department of Neurology, University of Florida College of Medicine, Gainesville, Florida
B.J. Wilder
Affiliation:
Neurology Service, Veterans Administration Hospital and Department of Neurology, University of Florida College of Medicine, Gainesville, Florida
*
Neurology Service (127), Veterans Administration Hospital, Gainesville, Florida 32602, U.S.A.
Rights & Permissions [Opens in a new window]

Summary

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Valproic acid in therapeutic doses was used in the treatment of postanoxic intention myoclonus. Disappearance of the myoclonus occurred with marked improvement in the electroencephalogram. No significant side effects were noted. Hepatic function tests were monitored. Determination of valproic acid plasma levels was used to guide therapy. Levels above 55 ßg were generally required. The patient remains free of myoclonus after four and one half months.

Type
Research Article
Information
Canadian Journal of Neurological Sciences , Volume 6 , Issue 1 , February 1979 , pp. 39 - 42
Copyright
Copyright © Canadian Neurological Sciences Federation 1979

References

Bedard, R. and Bouchard, R. (1974). Dramatic effect of methysergide on myoclonus. Lancet 1: 738.CrossRefGoogle ScholarPubMed
Boudin, G., Pepin, C.., Lauras, A., et al. (1963). Myoclonies intentionelles persistances apres reanimation cardiaque. Rev. Neurol. (Paris) 109: 468–472.Google Scholar
Bourdouresques, J., Roger, J., Khalil, R., et al. (1971). A propos de 2 observations de syndrome de Lance et Adams. Effect thérapeutique de RO-05-4023. Rev. Neurol. (Paris) 125: 306–309.Google Scholar
Bruni, J., Wilder, B. J., Willmore, L. J., et al. (1978) Steady-state Kinetics of Valproic Acid in Epileptic Patients. Clin. Pharmacol. Ther. 24: 324–332.CrossRefGoogle ScholarPubMed
Bruni, J., Wilder, B. J., Willmore, L. J., et al. (in press). Pharmacokinetics of steady state valproic acid in epileptic patients. J. Clin. Pharmacol. Ther.Google Scholar
Castaigne, P., Cambier, J., Escour-Olle, R., et al. (1964). Observation anatomoclinique d'un syndrome myocloni-que post-anoxique. Rev. Neurol. (Paris) 111: 60–73.Google Scholar
Chadwick, D., Reynolds, E. H. and Marsden, C. D. (1974). Relief of action myoclonus by 5-hydroxytryptophan. Lancet 2: 111–112.CrossRefGoogle ScholarPubMed
Delean, J., Richardson, J. C. and Hornykiewicz, O. (1976). Beneficial effects of serotonin precursors inpostanoxic action myoclonus. Neurology 26: 863–868.Google Scholar
Godin, Y., Heiner, L., Mark, J., et al. (1969). Effects of di-n-propylacetate, an anticonvulsant compound, on GABA metabolism. J. Neurochem. 16: 869–873.CrossRefGoogle ScholarPubMed
Goldberg, M. A. and Dormán, J. D. (1976). Intention myoclonus: Successful treatment with clonazepam. Neurology 26: 24–26, 1976.CrossRefGoogle Scholar
Growdon, J.H”young, R. R. and Shahani, B. T. (1976). L-5-hydroxytryp-tophan in the treatment of several different syndromes in which myoclonus is prominent. Neurology 26: 1135–1140.CrossRefGoogle ScholarPubMed
Guilleminault, C., Tharp, B.R. and Cousin, D. (1973). HVA and 5H1AACSF measurements of 5HTP trials in some patients with involuntary movements. J. Neurol. Sci. 18: 435–441.CrossRefGoogle ScholarPubMed
Halliday, A. M. (1975). The neurophysiol-ogy of myoclonic jerking — a reappraisal.In “Myoclonic Seizures”. Excerpta Medica Princeton, Ed. Charlton, M. H. pp. 1–29.Google Scholar
Harvey, P. K. P., Bradford, H. F. and Davison, A. N. (1975). The inhibitory effect of sodium n-dipropylacetate on the degradative enzymes of the GABA shunt. FEBS Lett. 52: 251–254.CrossRefGoogle Scholar
Hirose, G., Singer, P. and Bass, N. H. (1971). Successful treatment of posthypoxic action myoclonus with carbamazepine. J.A.M.A. 218: 1432–1433.CrossRefGoogle ScholarPubMed
Horton, R. W., Anlezark, G. M., Sawa, McB., et al. (1977). Monoamine and GABA metabolism and the anticonvulsant action of di-n-propylacetate and ethanolamine-O-sulphate. Eur. J. Pharmacol. 41: 387–397.CrossRefGoogle ScholarPubMed
Lance, J. W. and Adams, R. D. (1963). The syndrome of intention or action myoclonus as a sequel to hypoxic encephalopathy. Brain 86: 111–136.CrossRefGoogle ScholarPubMed
Lhermitte, F., Marteau, R. and Degos, C. F. (1972). Analyse pharmacolo-gique d'un nouveau cas de myoclonies d'intention et d'action post-anoxiques. Rev. Neurol. (Paris) 126: 107–114.Google Scholar
Lhermitte, F., Peterfalvi, M., Marteau, R., et al. (1971a). Analyse pharmacologique d'un cas de myoclonies d'intention et d'action post-anoxiques. Rev. Neurol. (Paris) 124: 21–31.Google Scholar
Lhermitte, F., Talairach, J., Buser, P., et al. (1971b). Myoclonies d'intention et d'action post-anoxiques. Etude stéréotaxique et destruction du noyau ventral lateral du thalamus. Rev. Neurol. (Paris) 124: 5–20.Google Scholar
Minoli, G. and Tredec1, G. (1974). Levodopa in treatment of myoclonus. Lancet 2: 472.CrossRefGoogle ScholarPubMed
Muller, H. R., Kaeser, H. E. and Dunant, J. H. (1967). Aspects cliniques et electrophysiologiques des myoclonies post-anoxiques, specialment du myoclonus d'action. Rev. Neurol. (Paris) 117: 105–110.Google Scholar
Perry, T. L., Berry, K.Hansen, S., et al. (1971). Regional distribution of amino acids in human brain obtained at autopsy. J. Neurochem. 18: 513–519.CrossRefGoogle ScholarPubMed
Sherwin, I. and Redmon, W. (1969). Successful treatment in action myoclonus. Neurology 19: 846–850.CrossRefGoogle ScholarPubMed
Van Woert, M. H. and Sethy, V. H. (1975). Therapy of intention myoclonus with L-5-hydroxytryptophan and a peripheral decarboxylase inhibitor, MK486. Neurology 25: 135–140.CrossRefGoogle Scholar
Van Woert, M. H., Rosenbaum, D., Howieson, J., et al. (1977). Long-term therapy of myoclonus and other neurologic disorders with L-5-hydroxytryptophan and carbidopa. N. Engl. J. Med. 296: 70–75.CrossRefGoogle ScholarPubMed
Villarreal, H. J., Wilder, B. J., Willmore, L.J., et al. (1978). Effect of valproic acid on spike and wave discharges in patients with absence seizures. Neurology. 28: 886–891.CrossRefGoogle ScholarPubMed
Willmore, L. J., Wilder, B. J., Bruni, J., et al. (1978). Effect of valproic acid on hepatic function. Neurology. 28: 961–964.CrossRefGoogle ScholarPubMed